Zimbabwe has turned down a major US health deal worth 367 million US dollars (£272m) over five years due to Washington's insistence on confidential biological samples.
This rejection came to light after a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesperson later explained that the United States was requesting genetic material for scientific study and commercial purposes but was unwilling to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued talks to secure a agreement suitable to both sides so the country's vital HIV programme can proceed.
Wider Background
This development follows a similar case in neighbouring Kenya, where a high court blocked a related deal with the US following legal challenges were filed about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
According to reports, 16 nations in Africa have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"In essence, our country would supply the raw materials for medical research with no certainty that the end products would be available to our population if a future pandemic arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending structures already established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This system is designed to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome further dialogue with our US partners on how future co-operation could be designed in a way that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but urged that negotiations must proceed considering much of the nation's HIV programmes relied on external financing.
"If specific concerns arise, such as those involving data governance or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it said.
This impasse highlights the complex tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more interconnected world.